Charlene Mantia - Dana-Farber Cancer Institute

基本信息

浏览量：4

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 71 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Examining Patient Characteristics in Bladder Cancer Clinical Trials Involving Immunotherapy

Izuagie Ikhapoh, Usomine Atairu, Amanda Jane Reich,Charlene M Mantia,Xiao X Wei,Rishi Sekar,Timothy N Clinton,Matthew Mossanen

Journal of clinical medicineno. 3 (2025)

引用0浏览0WOS引用

Phase 1 Expansion Results of IDE397, a First-in-class, Oral, MAT2A Inhibitor (mat2ai) in MTAP Deleted(del) Non-Small Cell Lung Cancer (NSCLC) and Urothelial Cancer (UC)

B. Herzberg, M. Johnson,C. G. Kim,A. Tolcher,J. Rodon,C. Mantia, J. Liu, A. Tripathi, L. Paz-Ares Rodriguez, T. De la Motte Rouge,C. M. Choi,J. Y. Han, L. Kwei, E. Liu,J. Sachdev, M. O'Quigley, M. White,D. Beaupre,H. R. Kim

EUROPEAN JOURNAL OF CANCER (2024): S176-S177

引用0浏览0引用

Comprehensive Multiplexed Autoantibody Profiling of Patients with Advanced Urothelial Cancer

Praful Ravi,Dory Freeman,Jonathan Thomas,Arvind Ravi,Charlene Mantia,Bradley A. Mcgregor,Jacob E. Berchuck,Ilana Epstein,Petra Budde,Behnaz Ahangarian Abhari,Elena Rupieper,Jana Gajewski,Ann-Sophie Schubert, Annika L. Kilian, Manuel Braeutigam,Hans-Dieter Zucht,Guru Sonpavde

JOURNAL FOR IMMUNOTHERAPY OF CANCERno. 2 (2024)

引用0浏览0WOS引用

TYRA-300, an Oral, FGFR3-selective Inhibitor: Preliminary Pharmacokinetic and Pharmacodynamic Analysis from SURF301, the Multicenter Open-Label Phase 1/2 Study of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Alterations

Y. Loriot, A. Zhang, A. Hansen,C. Mantia, V. Boni,A. Weickhardt,E. Y. Yu, M. Robert,G. Iyer, A. Murtha, S. Owens, B. Suttle,G. Vandekerkhove,A. Wyatt, G. Gammon,T. Burn,B. Tran

EUROPEAN JOURNAL OF CANCER (2024): S32-S33

引用0浏览0引用

35 (PB023): A Multicenter, Open-label Phase 1/2 Study of TYRA 300 in Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations (SURF301)

A. Zhang, V. Boni, A. Hanson,C. Mantia,A. Weickhardt, E. Yu, S. Gupta, M. Robert,G. Iyer,M. Millward,R. Morales-Barrera,C. Hoimes, J. Berlin, K. Mittal, A. Hill, F. Racca,D. Pouessel,C. Lihou,B. Tran,Y. Loriot

European Journal of Cancer（2024）

引用0浏览0引用

1994P Updated Efficacy Profile of the Double Antibody Drug Conjugate (DAD) Phase I Trial: Sacituzumab Govitecan (SG) Plus Enfortumab Vedotin (EV) in ≥ Second Line in Metastatic Urothelial Carcinoma (Muc)

B.A. McGregor,G.P. Sonpavde,L. Kwak, X. Gao,S. Berg,C. Mantia,X.X. Wei,P. Ravi,M.D. Michaelson,T.K. Choueiri,J. Bellmunt

Annals of Oncology (2024): S1153-S1154

引用0浏览0引用

Sacituzumab Govitecan (SG) Plus Enfortumab Vedotin (EV) for Metastatic Urothelial Carcinoma (muc) Treatment-Experienced (DAD) and with Pembrolizumab (P) in Treatment Naïve UC (DAD-IO)

Bradley Alexander McGregor,Lucia Kwak,Guru P. Sonpavde,Stephanie A. Berg,Toni K. Choueiri,Joaquim Bellmunt,Charlene Mantia

Journal of Clinical Oncology（2024）

引用0浏览0引用

Insulin Resistance During Androgen Deprivation Therapy in Men with Prostate Cancer

CANCERno. 21 (2024): 3671-3685

引用0浏览0WOS引用

154P Casdozokitug (casdozo, CHS-388), a First-in-class IL-27 Antagonistic Antibody, As Monotherapy in Treatment-Refractory Non-Small Cell Lung Cancer (NSCLC)

A. Naing,C. Mantia,N. Pennell,H.R. Kim,L. Villaruz,A.B. El-Khoueiry,D.E. Gerber,A. Qin,T-Y. Kim,M. Altan,L. Gandhi,S. Yoon, H. Tang, K. Iizuka, V. Kapoor, D. Chin,D. Morgensztern,T. Marron

Immuno-Oncology and Technology (2024): 100783

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn